Bromhexine
Based on 4 publication(s) in Google Scholar
Bromhexine is a potent expectorant. Bromhexine increase mucociliary clearance and reduces cough. Bromhexine can be used in study various respiratory diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.59%
- CAS No.: 3572-43-8
- 화학식: C14H20Br2N2
- 분자량:376.13
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Bromhexine
MoreAll Antibiotic Isoforms
More
Biological Activity
제품 설명
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3572-43-8
-
Appearance Solid
-
분자량 376.13
-
화학식 C14H20Br2N2
-
Color White to off-white
-
SMILES
BrC1=CC(Br)=CC(CN(C)C2CCCCC2)=C1N
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]2023 Jun:212:115554. PMID: 37080437 -
Int Immunopharmacol
A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killing. [Abstract]2021 Jul:96:107658. PMID: 33887610 -
BMJ Open Respir Res
Respiratory syncytial virus-induced SIGLEC1 upregulation inhibits macrophage autophagy and facilitates inflammatory mediator secretion. [Abstract]2026 Apr 20;13(1):e003586. PMID: 42009498 -
FEBS Lett
Bromhexine elevates REP2 expression to stimulate secretion from human primary conjunctiva fornix epithelial cells. [Abstract]2020 Jan;594(1):153-160. PMID: 31365127
Protocol
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
순도&문서
-
Data Sheet (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)